Trial Profile
A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activation Mutations.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Apr 2022 Planned End Date changed from 1 Sep 2022 to 30 Jun 2022.
- 04 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.